Aralia Guanxinkang Capsules Treatment Of Angina Pectoris With Qi Of Clinical Studies

In nowadays, coronary heart disease(CHD) has been the important cause of adults, death. It is in the first place of all kinds of dead causes in developed countries of economics and industrialization. The incidence rate and mortality of CHD are lower in our country than those countries, but with the development and changes of the society and economics, the incidence rate of CHD is in rising tendency year by year in most of regions, espicaliy in north and developed regions. So the prevention and cure of cardiovascular disease has been the important researchful subject of medicine in each country. As a important constitution of world-medicine, it is the main researchful direction of traditional Chinese medicine(TCM) of using wildings to treat disease and developing effective new drugs to prevent and cure chest pain, at present. Angina pectoris belongs to the"chest pain"or"heartache"category in TCM. Deficiency in origin and excess in superficiality and simultaneous occurrence of deficiency and excess syndromes is its main pathogenesis. Excess in superficiality are cold retained, qi stagnation, blood stasis and obstruction by phlegm. Deficiency in origin are deficiency of qi, blood, yin and yang. Deficiency of heart-qi is the essence of onset of disease and the key of pathogenesis. Qi can't promot circulation of blood because of deficiency of heart-qi, which leads to blood vessels stasis. Blood stasis due to qi deficiency is the most common pathogenesis of angina pectoris. This subject aims at this pathogenesis, uses the method of supplementing qi and activating blood to treat angina pectoris, observes the effect of Longya Guanxinkang capsule on myocardial ischemia, blood viscosity and endothelium's function and discuss part of it's clinical mechanism. Longya Congmu general saponin is the chief component of Longya Guanxinkang capsule. Longya Guanxinkang capsule has the function of supplementing qi to activate blood and removing blood stasis to relieve pain. And it can be applied to treat the syndrome of blood stasis due to qi deficiency. According to the Guidelines for Treatment of angina pectoris with traditional Chinese new medicine, GUIDELINES FOR NEW DRUG CLINICAL TRIALS (1997 Edition 3), we design this clinical trial, which is randomized, double-blind, double-simulated and controled. The patients from cardiovascular clinics Dept of DongZhiMen hospital are observed as the main obiect. NuoDiKang capsule is used as the control drug. We undertake this study in order to contrast the effects and side effects in treating angina pectoris patients with Longya Guanxinkang capsule and NuoDiKang capsule. A total of 48 angina pectoris patients with the syndrome of blood stasis due to qi deficiency are observed. They are divided into two groups by random. The treatment group and the control group both has 24 patients. There is no obvious difference in age, sex, illness course and severity degree between the two groups. After 4 weeks of treatment, the result indicates that the treatment group is better than control group in overall effective rate of angina pectoris (66.7% vs 62.5%), electrocadiogram effective rate (50% vs 45.8%), reducing use rate of Nitroglycerin (75% vs 66.7%) and overall effective rate of syndrom (83.3% vs 75%). But there is no statistical difference between the two groups (P>0.05). In symptoms of angina pectoris patients with the syndrome of blood stasis due to qi deficiency, the two groups can both relieve chest pain, chest stress, shortness of breath, et al. But the treatment group has more significant effects than control group in fatigue and lassitude (P<0.05). In hemorheology, the whole blood viscosity, red cell volume of pressure, plasma viscosity are improved in both groups and the two groups have significant difference after treatment compared with before treatment(P<0.01). Compared between the two groups, there is no statistical difference. In endothelium function, ET decreaces and CGRP rises after treatment. They are all better and have remarkable difference than before treatment (P<0.01...